Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

B
Babichev, Yael

Sinai Healthcare System
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Yael Babichev
Favorite
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Yael Babichev
Favorite
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Yael Babichev
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Yael Babichev
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Yael Babichev
Favorite
BABIN, Guillaume

Oncological department of Institut Bergonié
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Guillaume BABIN
Favorite
Badalamenti, Giuseppe

Policlinico P. Giaccone
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Giuseppe Badalamenti
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Giuseppe Badalamenti
Favorite
Badgett, Thomas

University of Kentucky College of Medicine
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Thomas Badgett
Favorite
Badiyan, Shahed

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Shahed Badiyan
Favorite
Baecklund, Fredrik

Stockholm, Karolinska University Hospital
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Fredrik Baecklund
Favorite
Baelde, Hans

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Hans Baelde
Favorite
Bae, Susie

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Susie Bae
Favorite
Bagaev, Alexander

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Alexander Bagaev
Favorite
Bagaria, Sanjay

Mayo Clinic
(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS
Sanjay Bagaria
Favorite
Bagué, Silvia

Hospital de la Santa Creu i Sant Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Silvia Bagué
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Silvia Bagué
Favorite
Bague, Silvia

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Silvia Bague
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Silvia Bague
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Silvia Bague
Favorite
Baia, Marco

Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Marco Baia
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Marco Baia
Favorite
Bailey, Kelly

University of Pittsburgh School of Medicine
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Kelly Bailey
Favorite
Baird, John

PTC Therapeutics, Inc.
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
John Baird
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
John Baird
Favorite
Bajpai, Jyoti

Tata Memorial Centre,Homibhabha National University,Mumbai,India
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Jyoti Bajpai
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Jyoti Bajpai
Favorite
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Jyoti Bajpai
Favorite
Baker, Benjamin

Peter MacCallum Cancer Centre
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
Benjamin Baker
Favorite
Bakker, Gertruud

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Gertruud Bakker
Favorite
Bakkila, Baylee

Yale University
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Baylee Bakkila
Favorite
Baldaccini, Davide

IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Davide Baldaccini
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Davide Baldaccini
Favorite
Baldazzi, Davide

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Davide Baldazzi
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Davide Baldazzi
Favorite
Baldi, Giacomo Giulio

Medical Oncology Department, "Santo Stefano" Hospital, Prato, Italy
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Giacomo Giulio Baldi
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Giacomo Giulio Baldi
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Giacomo Giulio Baldi
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Giacomo Giulio Baldi
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Giacomo Giulio Baldi
Favorite
Baldwin, Rebecca

Royal National Orthopaedic Hospital
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Rebecca Baldwin
Favorite
Baliga, Sujith

The Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Sujith Baliga
Favorite
Ballesteros-Perez, Alexandra

Certara
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Alexandra Ballesteros-Perez
Favorite
Ball, Howard

Ball Pharma Consulting Group
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Howard Ball
Favorite
Ballinger, Mandy

Garvan Institute of Medical Research
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Mandy Ballinger
Favorite
Ballman, Karla

Weil Cornell Graduate School of Medical Sciences
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Karla Ballman
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Karla Ballman
Favorite
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Karla Ballman
Favorite
Bambury, Richard

CUH
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Richard Bambury
Favorite
Banavali, Shripad D

Tata memorial Centre, Mumbai
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Shripad D Banavali
Favorite
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Shripad D Banavali
Favorite
Bandhlish, Anshu

University of Washington
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Anshu Bandhlish
Favorite
Banerjee, Jineta

Sage Bionetworks
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Jineta Banerjee
Favorite
Banerjee, Tamalina

University of Saskatchewan
(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Tamalina Banerjee
Favorite
Banini, Marco

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Marco Banini
Favorite
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Marco Banini
Favorite
Ban, Joy

Duke Univeristy
(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Joy Ban
Favorite
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Joy Ban
Favorite
Banuet Gonzalez, Diego

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Diego Banuet Gonzalez
Favorite
Banzato, Alberto

Cardiology Unit, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Alberto Banzato
Favorite
Bari, Elia

University of Eastern Piedmont - Department of Pharmaceutical Sciences
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Elia Bari
Favorite
Barisella, Marta

Department of Pathology,Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Marta Barisella
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Marta Barisella
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Marta Barisella
Favorite
Barkholt, Pernille

Adcendo ApS
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Pernille Barkholt
Favorite
Baron, Leigh-Ann

BC Cancer
(P 22) RECALL EXPERIENCE FOR SURVIVORS OF PEDIATRIC RHABDOMYOSARCOMA TREATED AT A SINGLE INSTITUTION BETWEEN 1970 AND 2010
Leigh-Ann Baron
Favorite
Baron, Max

University of Miami
(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS
Max Baron
Favorite
Barreto coelho, Priscila

University of Miami
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Priscila Barreto coelho
Favorite
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Priscila Barreto coelho
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Priscila Barreto coelho
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Priscila Barreto coelho
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Priscila Barreto coelho
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Priscila Barreto coelho
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Priscila Barreto coelho
Favorite
Barretta, Francesco

Fondazione IRCCS IStituto Nazionale dei Tumori, Milan, Italy
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Francesco Barretta
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Francesco Barretta
Favorite
Barrientos De Renshaw, Tomasa

Duke University
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Tomasa Barrientos De Renshaw
Favorite
Barrus, Joshua

The Ohio State University Wexner Medical Center
(P 311) ROBUST VMAT TREATMENT PLANNING FOR EXTREMITY SOFT TISSUE SARCOMAS
Joshua Barrus
Favorite
Barry, Janie

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Janie Barry
Favorite
Bartelstein, Meredith

Memorial Sloan-Kettering Cancer Center
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Meredith Bartelstein
Favorite
Bartholomew, Alex

Duke University
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Alex Bartholomew
Favorite
Bartlett, Edmund

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Edmund Bartlett
Favorite
(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Edmund Bartlett
Favorite
(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS
Edmund Bartlett
Favorite
Barve, Rahul

Memorial Sloan Kettering Cancer
(P 323) PERIPHERAL NEUROPATHY FOLLOWING INTRA-OPERATIVE RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Rahul Barve
Favorite
Barwad, Adarsh

Department of Pathology, All India Institute of Medical Sciences
(P 562) A PHASE 2, SINGLE ARM STUDY OF REGORAFENIB IN METASTATIC/UNRESECTABLE REFRACTORY SYNOVIAL SARCOMAS
Adarsh Barwad
Favorite
Basar, Rafet

University of Texas MD Anderson
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Rafet Basar
Favorite
Basi, Akshay

The University of Texas MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Akshay Basi
Favorite
Basile, Georges

University of Montreal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Georges Basile
Favorite
Basile, Georges

Hôpital Maisonneuve-Rosemont
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Georges Basile
Favorite
Basso, Umberto

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Umberto Basso
Favorite
Bastucci, Silvia

IRCCS Istituto Nazionale Tumori Regina Elena
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Silvia Bastucci
Favorite
Basu Mallick, Atrayee

Thomas Jefferson University Hospital
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Atrayee Basu Mallick
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Atrayee Basu Mallick
Favorite
Bauer, Sebastian

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Sebastian Bauer
Favorite
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Sebastian Bauer
Favorite
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Sebastian Bauer
Favorite
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Sebastian Bauer
Favorite
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Sebastian Bauer
Favorite
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Sebastian Bauer
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Sebastian Bauer
Favorite
(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Sebastian Bauer
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Sebastian Bauer
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Sebastian Bauer
Favorite
Baumhoer, Daniel

University Hospital Basel
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Daniel Baumhoer
Favorite
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Daniel Baumhoer
Favorite
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Daniel Baumhoer
Favorite
Beale, Philip

Concord Repatriation General Hospital
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Philip Beale
Favorite
Beamer, Staci

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Staci Beamer
Favorite
Beane, Joal

The James Cancer Hospital / The Ohio State University
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Joal Beane
Favorite
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Joal Beane
Favorite
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Joal Beane
Favorite
Beaupin, Lynda

Johns Hopkins All Children's Hospital
(P 193) Recent Trends in Sarcoma Trials for Children in the United States
Lynda Beaupin
Favorite
Beckingsale, Thomas

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Thomas Beckingsale
Favorite
Bedi, Meena

Medical College of Wisconsin
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
Meena Bedi
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Meena Bedi
Favorite
Bedke, Jens

Klinikum Stuttgart
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Jens Bedke
Favorite
Bedniagin, Lev

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Lev Bedniagin
Favorite
Beeram, Murali

START Center for Cancer Care
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Murali Beeram
Favorite
Beggs, Andrew

University of Birmingham
(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Andrew Beggs
Favorite
Beird, Hannah

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Hannah Beird
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Hannah Beird
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Hannah Beird
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Hannah Beird
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Hannah Beird
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Hannah Beird
Favorite
Beishuizen, Auke

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Auke Beishuizen
Favorite
Belayneh, Rebekah

University of Pittsburgh Medical Center
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Rebekah Belayneh
Favorite
Belda Sanchis, Josep

Hospital de la Santa Creu i Sant Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Josep Belda Sanchis
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Josep Belda Sanchis
Favorite
Belinchon, Belén

HU La Paz
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Belén Belinchon
Favorite
Belinsky, Martin

Fox Chase Cancer Center
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Martin Belinsky
Favorite
Bell, John

University of Ottawa
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
John Bell
Favorite
Bello, Alexa

The University of Texas MD Anderson Cancer Center
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Alexa Bello
Favorite
Bellotti, Chiara

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Chiara Bellotti
Favorite
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Chiara Bellotti
Favorite
Bell, Timothy

SpringWorks Therapeutics, Inc.
(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY
Timothy Bell
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Timothy Bell
Favorite
Bell, Zoe

Newcastle University
(P 298) EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA
Zoe Bell
Favorite
Beltran, Joan

Cebiotex S.L., Barcelona, Spain
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Joan Beltran
Favorite
Belzberg, Allan

Johns Hopkins University
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Allan Belzberg
Favorite
Benaoudia, Sacha

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Sacha Benaoudia
Favorite
Ben-Arush, Myriam

Rambam Medical Center, Joan and Sanford Weill Pediatric Hematology Oncology and Bone Marrow Transplantation Division, Ruth Rappaport Children's Hospital, Haifa
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Myriam Ben-Arush
Favorite
Bender, Lewis

Intensity Therapeutics Inc.
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Lewis Bender
Favorite
Benini, Stefania

Department of Pathology, IRCCS Istituto Ortopedico Rizzoli
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Stefania Benini
Favorite
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Stefania Benini
Favorite
Benjamin, Robert

The University of Texas MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Robert Benjamin
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Robert Benjamin
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Robert Benjamin
Favorite
Benson, charlotte

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
charlotte Benson
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
charlotte Benson
Favorite
Benzonelli, Irene

San Luigi Hospital
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Irene Benzonelli
Favorite
Berclaz, Luc

Department of Internal Medicine III, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Luc Berclaz
Favorite
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Luc Berclaz
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Luc Berclaz
Favorite
Bergamaschi, Laura

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Laura Bergamaschi
Favorite
Berg, Rachel

Tempus Labs, Inc
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Rachel Berg
Favorite
Berg, Stephanie

Dana Farber Cancer Institute
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Stephanie Berg
Favorite
Berlanga, Pablo

Gustave Roussy Cancer Centre
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Pablo Berlanga
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Pablo Berlanga
Favorite
Bernabé, María José

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
María José Bernabé
Favorite
Bernabeu, Daniel

HU La Paz
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Daniel Bernabeu
Favorite
Bernard-Bedard, Ericka

Department of Surgery, University of Ottawa
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Ericka Bernard-Bedard
Favorite
Bernard-Gauthier, Vadim

Bayer Pharmaceuticals, Inc.
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Vadim Bernard-Gauthier
Favorite
Berner, Jeanne-Marie

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Jeanne-Marie Berner
Favorite
Bernthal, Nicholas

University of California Los Angeles
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Nicholas Bernthal
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Nicholas Bernthal
Favorite
Berruti, Alfredo

University of Brescia, ASST Spedali Civili
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Alfredo Berruti
Favorite
Berthiaume, Marie-Josée

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Marie-Josée Berthiaume
Favorite
Bertulli, Rossella

Mesenchymal and rare cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Rossella Bertulli
Favorite
(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Rossella Bertulli
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Rossella Bertulli
Favorite
Bertuzzi, Alexia

Humanitas Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Alexia Bertuzzi
Favorite
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Alexia Bertuzzi
Favorite
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Alexia Bertuzzi
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Alexia Bertuzzi
Favorite
BESSEDE, Alban

Explicyte
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Alban BESSEDE
Favorite
Betel, Doron

Weill Cornell Medicine Graduate School of Medical Sciences
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Doron Betel
Favorite
Bethell, Mikhail

Duke University School of Medicine
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Mikhail Bethell
Favorite
Beumer, Jan

University of Pittsburgh Medical Center
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Jan Beumer
Favorite
Bezerra, Tiago

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Tiago Bezerra
Favorite
Bhachech, Niraja

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Niraja Bhachech
Favorite
Bhadri, Vivek

Chris O'Brien Lifehouse
(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Vivek Bhadri
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Vivek Bhadri
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Vivek Bhadri
Favorite
Bhalla, Angela

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Angela Bhalla
Favorite
Bhatia, Himanshi

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Himanshi Bhatia
Favorite
Bhise, Shruti

Fred Hutchinson Cancer Center
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Shruti Bhise
Favorite
Bhogal, Sumail

University of Pittsburgh Medical Center
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Sumail Bhogal
Favorite
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Sumail Bhogal
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Sumail Bhogal
Favorite
Bialick, Steven

Sylvester Comprehensive Cancer Center, University of Miami
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Steven Bialick
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Steven Bialick
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Steven Bialick
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Steven Bialick
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Steven Bialick
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Steven Bialick
Favorite
Bianchi, Giuseppe

Istituto Ortopedico Rizzoli IOR IRCCS, SC Third Orthopaedic Clinic and Traumatology, Bologna Italy
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Giuseppe Bianchi
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Giuseppe Bianchi
Favorite
Bickley, Sorrel

Sarcoma UK
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Sorrel Bickley
Favorite
(P 150) VISUALISING SOFT TISSUE SARCOMA INCIDENCE DATA FOR PATIENT EMPOWERMENT
Sorrel Bickley
Favorite
(P 151) DEVELOPMENT AND IMPACT OF A PRIMARY CARE SARCOMA EDUCATION MODULE FOR ENGLAND AND WALES
Sorrel Bickley
Favorite
Bidgoli, Mahtab

Skåne University Hospital
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Mahtab Bidgoli
Favorite
Bielack, Stefan

Olgahospital Stuttgart
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Stefan Bielack
Favorite
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Stefan Bielack
Favorite
Bien, Jeffrey

Stanford University School of Medicine
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Jeffrey Bien
Favorite
Bie, Yuan

University of Guelph
(P 304) A COMPARATIVE ANALYSIS OF METABOLIC FLEXIBILITY IN OSTEOSARCOMA CELLS
Yuan Bie
Favorite
Biffart, Brookelyn

University of British Columbia
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Brookelyn Biffart
Favorite
Bilska, Katarzyna

Department of Oncology and Surgical Oncology for Children and Youth, Mother and Child Institute, 01-211 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Katarzyna Bilska
Favorite
Bingham, Justus

Momentum Metrix
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Justus Bingham
Favorite
Bini, Marta

INT Milan
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Marta Bini
Favorite
Binitie, Odion

H. Lee Moffitt Cancer Center
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Odion Binitie
Favorite
(P 511) SIGNIFICANCE OF TIP TO APEX DISTANCE IN PATHOLOGICAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Odion Binitie
Favorite
Biondi, Nicola

Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Nicola Biondi
Favorite
Bird, Justin

The University of Texas MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Justin Bird
Favorite
Birz, Suzi

University of Chicago
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Suzi Birz
Favorite
Bishop, Andrew

MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Andrew Bishop
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Andrew Bishop
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Andrew Bishop
Favorite
Bisig, Bettina

CHUV
(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
Bettina Bisig
Favorite
Bisogno, Gianni

Department of Pediatric Haematology and Oncology, University Hospital of Padua
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Gianni Bisogno
Favorite
Bjerkehagen, Bodil

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Bodil Bjerkehagen
Favorite
Bjornard, Kari

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 15) INTRAOSSEOUS RHABDOMYOSARCOMA OF THE CHEST WITH FUS:TFCP2 FUSION AND GERMLINE VARIANTS IN NF1 AND SBDS: NOVEL LOCATION AND MOLECULAR CHARACTERISTICS OF A RARE TUMOR
Kari Bjornard
Favorite
Black, Ralph

Fred Hutchinson Research Center
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Ralph Black
Favorite
Blakaj, Dukagjin

The Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Dukagjin Blakaj
Favorite
Blakeley, Jaishri

Johns Hopkins University
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Jaishri Blakeley
Favorite
Blakely, Andrew

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Andrew Blakely
Favorite
Blanco Alcaina, Elena

Institute of Biomedicine of Sevilla, IBIS, Hospital Universitario Virgen del Rocío-HUVR, Consejo Superior de Investigaciones Científicas-CSIC
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Elena Blanco Alcaina
Favorite
Blank, Alan

Rush University Medical Center
(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Alan Blank
Favorite
(P 232) NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY
Alan Blank
Favorite
(P 307) IS RADIOTHERAPY NECESSARY FOR MANAGEMENT OF LOW GRADE MYXOID LIPOSARCOMA? A SYSTEMATIC REVIEW
Alan Blank
Favorite
(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS
Alan Blank
Favorite
(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Alan Blank
Favorite
(P 468) OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE
Alan Blank
Favorite
(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Alan Blank
Favorite
Blankenship, Kaley

St. Jude Children's Research Hospital
(P 288) EVALUATION OF ATR AND WEE1 INHIBITORS COMBINED WITH NANO-LIPOSOMAL IRINOTECAN IN A LARGE COHORT OF RHABDOMYOSARCOMA XENOGRAFTS USING A TWIN MOUSE PRECLINICAL TRIAL DESIGN
Kaley Blankenship
Favorite
(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Kaley Blankenship
Favorite
Blattmann, Claudia

Olgahospital
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Claudia Blattmann
Favorite
Blay, Jean-Yves

Centre Léon-Bérard
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Jean-Yves Blay
Favorite
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Jean-Yves Blay
Favorite
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Jean-Yves Blay
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Jean-Yves Blay
Favorite
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Jean-Yves Blay
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Jean-Yves Blay
Favorite
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Jean-Yves Blay
Favorite
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Jean-Yves Blay
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Jean-Yves Blay
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Jean-Yves Blay
Favorite
Blazer, Dan

Duke University
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Dan Blazer
Favorite
(P 340) CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA
Dan Blazer
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Dan Blazer
Favorite
Bleckman, Roos

University medical center Groningen
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Roos Bleckman
Favorite
Bleris, Leonidas

Department of Bioengineering, University of Texas at Dallas
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Leonidas Bleris
Favorite
Bloem, Johan

Leiden University Medical Center
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Johan Bloem
Favorite
Blonski, Piotr

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Piotr Blonski
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Piotr Blonski
Favorite
Blum, Kelly

UCSF
(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS
Kelly Blum
Favorite
Bobak, Klaudia

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Klaudia Bobak
Favorite
Boikos, Sosipatros

Georgetown Lombardi Comprehensive Cancer Center
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Sosipatros Boikos
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Sosipatros Boikos
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Sosipatros Boikos
Favorite
Boi, Laurens

Ghent University
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Laurens Boi
Favorite
BOLLARD, julien

Centre Léon Bérard
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
julien BOLLARD
Favorite
Bolshinsky, Maital

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Maital Bolshinsky
Favorite
Bonaparte, Ilaria

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy
(P 309) CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA
Ilaria Bonaparte
Favorite
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Ilaria Bonaparte
Favorite
Bone, Jeffrey

British Columbia Children's Hospital Research Institute
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Jeffrey Bone
Favorite
Bonel, Martina

Azienda Ospedale - Università Padova
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Martina Bonel
Favorite
Bonenkamp, Han

Radboud university medical center
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Han Bonenkamp
Favorite
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Han Bonenkamp
Favorite
Bonvalot, Sylvie

Institut Curie
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Sylvie Bonvalot
Favorite
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Sylvie Bonvalot
Favorite
Boonstra-Schelfhorst, Maaike

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Maaike Boonstra-Schelfhorst
Favorite
Borcherding, Dana

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Dana Borcherding
Favorite
Borchert, Sabrina

Institute of Pathology, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Sabrina Borchert
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Sabrina Borchert
Favorite
Borghi, Alessandra

Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Alessandra Borghi
Favorite
Borinstein, Scott

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Scott Borinstein
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Scott Borinstein
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Scott Borinstein
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Scott Borinstein
Favorite
Borkowska, Aneta

Maria Sklodowska-Curie National Research Institute of Oncology
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Aneta Borkowska
Favorite
Borkowska, Aneta

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 95) LONG-TERM OUTCOMES OF PATIENTS DIAGNOSED WITH CHORDOMA OF THE SACRUM
Aneta Borkowska
Favorite
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Aneta Borkowska
Favorite
Borkowska, Aneta

Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw Poland
(P 310) PREOPERATIVE RADIOTHERAPY WITH HYPERTHERMIA IN RECURRENT AND RADIATION-INDUCED SARCOMAS: RESULTS OF A PHASE 2 CLINICAL TRIAL
Aneta Borkowska
Favorite
(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Aneta Borkowska
Favorite
Bossard, Carine

BioSplice
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Carine Bossard
Favorite
Bouchoucha, Yassine

Institute Curie
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Yassine Bouchoucha
Favorite
Boudadi, Karim

Johns Hopkins University School of Medicine
(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Karim Boudadi
Favorite
Boughdad, sarah

CHUV
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
sarah Boughdad
Favorite
Boukovinas, Ioannis

Department of Medical Oncology, Bioclinic Hospital, 54622 Thessaloniki, Greece
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Ioannis Boukovinas
Favorite
Boulva, Kerianne

The Centre hospitalier de l'Université de Montréal (CHUM)
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Kerianne Boulva
Favorite
BOURDON, Aurélien

Institut Bergonié
(P 300) ANTI-TUMOR ACTIVITY OF PARP7 INHIBITOR RBN-2397 IN SOFT-TISSUE SARCOMAS
Aurélien BOURDON
Favorite
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Aurélien BOURDON
Favorite
Bournat, Juan

MD Anderson Cancer Center
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Juan Bournat
Favorite
Bouzein, Kathryn

University of Chicago
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Kathryn Bouzein
Favorite
Bovee, Judith

LUMC
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Judith Bovee
Favorite
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Judith Bovee
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Judith Bovee
Favorite
Boye, Kjetil

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Kjetil Boye
Favorite
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Kjetil Boye
Favorite
Bränström, Robert

Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Robert Bränström
Favorite
Braga, Daniele

humanitas research hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Daniele Braga
Favorite
Brahmi, Mehdi

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Mehdi Brahmi
Favorite
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Mehdi Brahmi
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Mehdi Brahmi
Favorite
Bramanti, Stefania

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Stefania Bramanti
Favorite
Brar, Savtaj

Mount Sinai Hospital
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Savtaj Brar
Favorite
Braun, Katherine

Seattle Children's Research Institute
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Katherine Braun
Favorite
Breckenridge, Zackariah

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Zackariah Breckenridge
Favorite
Brennan, Bernadette

Royal Manchester Children's Hospital
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Bernadette Brennan
Favorite
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Bernadette Brennan
Favorite
Bresler, Scott

Department of Pathology, University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Scott Bresler
Favorite
Bretcha, Pedro

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Pedro Bretcha
Favorite
Briaire-de Bruijn, Inge

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Inge Briaire-de Bruijn
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Inge Briaire-de Bruijn
Favorite
Brichard, Bénédicte

Cliniques Universitaires Saint Luc
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Bénédicte Brichard
Favorite
Brich, Silvia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Silvia Brich
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Silvia Brich
Favorite
Brigham, Don

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Don Brigham
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Don Brigham
Favorite
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Don Brigham
Favorite
Brigman, Brian

Duke University
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Brian Brigman
Favorite
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Brian Brigman
Favorite
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Brian Brigman
Favorite
Brinkmann, Elyse

University of Washington
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Elyse Brinkmann
Favorite
Brito, Ariadna

Cancer Research Center of Toulouse
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Ariadna Brito
Favorite
Britschgi, Christian

University Hospital Zurich
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Christian Britschgi
Favorite
Brockman, Qierra

University of Iowa
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Qierra Brockman
Favorite
Brodeur, Garrett

University of Pennsylvania Perelman School of Medicine; Children's Hospital of Philadelphia
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Garrett Brodeur
Favorite
Brodowicz, Thomas

Medical University of Vienna
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Thomas Brodowicz
Favorite
Broida, Samuel

Mayo Clinic (Rochester)
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Samuel Broida
Favorite
(P 59) CHONDROSARCOMA OF THE FLAT BONES: DIFFERENTIAL SURVIVAL BETWEEN HIGH GRADE LESIONS OF THE PELVIS AND SCAPULA
Samuel Broida
Favorite
(P 60) SKIP LESIONS IN CHONDROSARCOMA: IS WHOLE BONE IMAGING NECESSARY?
Samuel Broida
Favorite
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Samuel Broida
Favorite
(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT
Samuel Broida
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Samuel Broida
Favorite
Broida, Samuel

Mayo Clinic
(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Samuel Broida
Favorite
Brookes, Marcus

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Marcus Brookes
Favorite
Brookes, Marcus

Northern Bone and Soft Tissue Tumour Service
(P 298) EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA
Marcus Brookes
Favorite
(P 522) FLUORESCENCE GUIDED SURGERY WITH INDOCYANINE GREEN FOR SURGICAL RESECTION OF METASTATIC BONE AND SOFT TISSUE TUMOURS: A CASE SERIES
Marcus Brookes
Favorite
Broomfield, Jaye

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Jaye Broomfield
Favorite
Brosjö, Otte

Karolinska University Hospital
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Otte Brosjö
Favorite
Brotea-Mosoiu, Silvia

Oncology Institute of Bucharest
(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Silvia Brotea-Mosoiu
Favorite
Brouste, Véronique

Institut Bergonié
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Véronique Brouste
Favorite
Brown, Amber

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 15) INTRAOSSEOUS RHABDOMYOSARCOMA OF THE CHEST WITH FUS:TFCP2 FUSION AND GERMLINE VARIANTS IN NF1 AND SBDS: NOVEL LOCATION AND MOLECULAR CHARACTERISTICS OF A RARE TUMOR
Amber Brown
Favorite
Browne, MaKenna

Duke University
(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS
MaKenna Browne
Favorite
(P 450) INVESTIGATING THE THERAPEUTIC POTENTIAL OF SMALL MOLECULE INHIBITOR INOBRODIB AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
MaKenna Browne
Favorite
Brown, Jeffrey

Huntsman Cancer Institute
(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE
Jeffrey Brown
Favorite
Brown, Jeffrey

Huntsman Cancer Institute, University of Utah
(P 246) IMMUNOCOMPETENT MODELING OF PLEOMORPHIC LIPOSARCOMA
Jeffrey Brown
Favorite
Brown, Samuel

University of Calgary
(P 415) NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Samuel Brown
Favorite
Brugarolas, Antonio

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Antonio Brugarolas
Favorite
Brugières, Laurence

Gustave Roussy Cancer Campus
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Laurence Brugières
Favorite
Brunello, Antonella

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Antonella Brunello
Favorite
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Antonella Brunello
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Antonella Brunello
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Antonella Brunello
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Antonella Brunello
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Antonella Brunello
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Antonella Brunello
Favorite
Brusco, Silvia

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Silvia Brusco
Favorite
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Silvia Brusco
Favorite
Buac, Neil

Rush University Medical Center
(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Neil Buac
Favorite
Buchan, Ann

The Christie NHS Foundation Trust
(P 190) DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE
Ann Buchan
Favorite
(P 337) CLINICAL OUTCOME OF THE PATIENTS WITH HIGH GRADE UTERINE SARCOMA: A SINGLE CENTRE REAL WORLD EXPERIENCE
Ann Buchan
Favorite
Budd, George

Cleveland Clinic
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
George Budd
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
George Budd
Favorite
Buendia, Javier

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Javier Buendia
Favorite
Bui, Nam

Stanford University
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Nam Bui
Favorite
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Nam Bui
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Nam Bui
Favorite
Bulgarelli, jenny

IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" S.r.l.
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
jenny Bulgarelli
Favorite
Bult, Carol J

The Jackson Laboratory
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Carol J Bult
Favorite
Bulusu, Ramesh

Department of Medical Oncology, Cambridge University Hospitals NHS Foundation Trust
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Ramesh Bulusu
Favorite
Buonomenna, Ciriaco

Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Ciriaco Buonomenna
Favorite
Burcoveanu, Domnita-Ileana

Bayer HealthCare Pharmaceuticals, Inc.
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Domnita-Ileana Burcoveanu
Favorite
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Domnita-Ileana Burcoveanu
Favorite
Burgess, Melissa

University of Pittsburgh Medical Center Hillman Cancer Center
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Melissa Burgess
Favorite
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Melissa Burgess
Favorite
Burgoyne, Adam

Department of Medicine, Division of Hematology-Oncology, UC San Diego Health
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Adam Burgoyne
Favorite
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Adam Burgoyne
Favorite
Burke, Chelsey

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Chelsey Burke
Favorite
Burke, Zachary

Celveland Clinic Sarcoma Program
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Zachary Burke
Favorite
(P 242) WHOLE BODY PET/MRI FOR STAGING OF MYXOID LIPOSARCOMA
Zachary Burke
Favorite
(P 402) TISSUE PERFUSION AND WOUND HEALING AFTER SOFT TISSUE SARCOMA RESECTION
Zachary Burke
Favorite
(P 513) THE IMPACT OF MARGIN STATUS ON THE ONCOLOGIC OUTCOMES OF SURGICALLY TREATED DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES
Zachary Burke
Favorite
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Zachary Burke
Favorite
Burkhard-Meier, Anton

Department of Internal Medicine III, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Anton Burkhard-Meier
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Anton Burkhard-Meier
Favorite
Burks, Jared

The University of Texas MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Jared Burks
Favorite
Burlile, Jessica

Mayo Clinic Minnesota
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Jessica Burlile
Favorite
Burner, Danielle

Duke University
(P 340) CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA
Danielle Burner
Favorite
Burns, Jessica

The Institute of Cancer Research
(P 404) PROTEOMIC PROFILING OF THE SOFT TISSUE SARCOMA MICROENVIRONMENT IDENTIFIES A PROGNOSTIC SIGNATURE BASED ON PROTEOGLYCAN EXPRESSION AND CD8+ TUMOUR INFILTRATING LYMPHOCYTES
Jessica Burns
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Jessica Burns
Favorite
Burris, Howard

Sarah Cannon Research Institute
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Howard Burris
Favorite
Bustos, Ana

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Ana Bustos
Favorite
Buxton, Allen

Public Health Institute, Children's Oncology Group
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Allen Buxton
Favorite
Buzzaccarini, Maria Samaritana

Radiation Therapy Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Maria Samaritana Buzzaccarini
Favorite
Byrd, Precious

MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Precious Byrd
Favorite